Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review
Why the study?
Do antidiabetic agents affect mortality and harm in patients with diabetes and heart failure?
Population
patients with diabetes and heart failure
Design
Systematic_review
Authors
Discussion
Loading...
Member takes
Implication
Supports metformin preference in diabetes with heart failure; extends evidence of its unique safety and mortality signal.
Key Points
- The aim is to evaluate the benefits and harms of antidiabetic agents in patients with diabetes and heart failure.
- Conducted a systematic review of studies related to antidiabetic agents and heart failure
- Evaluated the association of metformin with mortality
- Reviewed three studies for overall findings.
- Metformin was the only antidiabetic agent not associated with harm
- It showed reduced all-cause mortality in two out of three studies.
Structured PICO
Do antidiabetic agents affect mortality and harm in patients with diabetes and heart failure?
P
Population
patients with diabetes and heart failure
I
Intervention
antidiabetic agents (including metformin)
O
Outcome
all cause mortalityhard clinical
Metformin appears to be the only safe antidiabetic agent in patients with concurrent diabetes and heart failure, potentially reducing all-cause mortality.
Cite This Study
Eurich et al. (2007) studied this question.